As In-PharmaTechnologist.com previously reported, the company will spend $9m to add large-scale manufacturing capability as its API production facility in Karlskoga, Sweden.
“This investment is in response to an increase in demand for larger scale, multi-purpose manufacturing capabilities,” a spokesperson from the company told this publication.
Specifically, there continues to be high demand for US- and European-based suppliers with large scale cGMP contract manufacturing capacity and “world class quality systems.”
Prior to investing in the new facility, the company considered several factors, such as the value of the products manufactured, the customer base and the customers’ current and anticipated requirements, location, in addition to operating costs.
According to the company spokesperson, Cambrex is confident that the expansion “will be well utilized.”
In addition to its investment in Karlskoga, the company recently completed construction on a $50m production and warehousing expansion at its Charles City, Iowa-based cGMP site.
“We believe that our recent investments, combined with a very talented and experienced team, provides an ongoing foundation for our customers’ small molecule product manufacturing needs while supporting our goal of bringing our customers’ products to market quickly,” the Cambrex spokesperson said.
“As overall industry trends remain favorable, we will continue to invest to increase our small and large scale capabilities.”